For patients with bone metastasis, bone-targeting agents (BTAs), such as bisphosphonate (zoledronic acid) and RANK-L inhibitors (denosumab), are found to improve bone pain and reduce the development of skeletal-related events (SREs) by restoring the physiological bone turnover [3]. This evidence concerns the gene TNFSF11 and bone metastasis.